Navigation Links
CeNeS Pharmaceuticals Plc Announces Preliminary Results for The,Year Ending 31 December 2006

Preliminary results for the year ended 31 December 2006

Product profile of lead drug candidate confirmed in large Phase III study International partnering process to commerialise M6G underway

CAMBRIDGE, England, March 28, 2007 - CeNeS Pharmaceuticals plc ("CeNeS" or "the Company"), the CNS focused developing specialty pharmaceutical company, today announces its preliminary results for the year ended 31 December 2006.

Operational Highlights

Clinical pipeline

M6G - post-operative pain

* Successful major Phase III study results announced

* showing clear benefits over morphine in management of post-operative pain * demonstrates the unique product profile

* IND submitted to FDA in March 2007 * Strengthened M6G intellectual property position * Actively pursuing M6G partnering deals

CNS 5161 - cancer pain and neuropathic pain

* Signed Revenue Sharing and Co-Development agreement with ERGOMED * PhaseI/II cancer pain study to start recruitment in mid 2007 * Second Phase II study in neuropathic pain to start later in 2007 * Phase II clinical supply manufacturing completed early 2007 * Acquisition of transdermal patch formulation IP enabling development of high value transdermal formulation for neuropathic pain

Pre-clinical/discovery pipeline

CNS 7056 - short acting sedation/anaesthesia

* Japanese, Hong Kong and European patents granted for short acting sedative * Encouraging pre-clinical studies

* reveal rapid onset and offset of sedative action and rapid metabolism * support the potential to expand the indications into anaesthesia

* Further studies in anaesthesia initiated with a large pharmaceutical company * The first CNS 7056 academic paper has been accepted for publication in "Anesthesiology" a leading journal

COMT inhibitors - Parkinson's disease

* Pre-clinical development candidate for Parkinson's
'"/>




Page: 1 2 3

Related medicine technology :

1. Major New Review Supports the Broader Potential of CeNeS COMT Inhibitor Discovery Programme
2. Independent publication supports the profile of CeNeS phase II compound, CNS 5161
3. CeNeS Pharmaceuticals plc: Update on Successful Phase III results announced on Lead Product M6G
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:7/31/2014)... Conn. , July 31, 2014  UBM Medica ... a leading online community for oncologists, presents exclusive slide ... that are essential to quality cancer care. ... journal ONCOLOGY , offers news, blogs, and podcasts ... for oncologists highlighting quality cancer care: , End-of-life ...
(Date:7/31/2014)... , July 31, 2014  Decision Resources Group is ... intelligence product Marketrack to now include ChinaTrack; the new ... landscape in an interactive dashboard providing detailed brand-level share ... at a hospital level. Other key capabilities ... data feed: In addition to end-user surveys of healthcare ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 2Cancer Network Highlights Methods Oncologists Can Use to Improve Communication 3Decision Resources Group Announces First Medical Device Account Targeting Tool in China 2Lazarus Effect Closes $5 Million Financing 2
... CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 6, 2007 - CombinatoRx,Incorporated ... its,randomized, blinded, placebo-controlled phase 2 clinical trials ... rheumatoid,arthritis (RA) will be featured at the ... Rheumatology meeting, June,13-16, 2007 in Barcelona, Spain., ...
... study results confused the public about the,need and ... /PRNewswire/ -- The onslaught of,anti-stent news reports over ... that angioplasty doesn't work and its use should,decrease. ... their cardiologists about the benefits of stenting. , ...
Cached Medicine Technology:Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 2Novel Mechanism Insights and Additional Data on CombinatoRx Drug,Candidates to Be Presented at Upcoming EULAR Meeting 3To Stent or Not: Is That the Question? 2
(Date:8/1/2014)... (PRWEB) August 01, 2014 Register to join ... of the most active years on record for life sciences ... life sciences represented 22 percent of all venture dollars spent ... and achieved high valuations. , However, 2014 is proving ... recent report by Silicon Valley Bank, while life sciences IPOs ...
(Date:7/31/2014)... HEIGHTS, Ill. (August 1, 2014) Women over the ... an increased risk for obesity, greater struggles against poverty ... An article published in the August issue of ... publication of the American College of Allergy, Asthma and ... in treating asthma, and offers practical solutions to improve ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... (PRWEB) July 31, 2014 Ce-Classes.com has ... education course for healthcare professionals, a Systematic Review ... upon material published in the International Journal of Clinical ... created in response to a need to have accurate ... provide the best treatment possible. The material provides ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
Breaking Medicine News(10 mins):Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 2Health News:Register to Join the Merrill DataSite's Webinar - Built to Sell: The Life Sciences Deal Climate 3Health News:Female baby boomers with asthma? You may need help 2Health News:Female baby boomers with asthma? You may need help 3Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Company Provides New Course on Sexual Satisfaction 2Health News:Company Provides New Course on Sexual Satisfaction 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... (non-steroidal anti- inflammatory drug) treatment that can be applied directly to site of ... osteoarthritis pain * Voltaren Gel ... knees and the joints ... of the hands * Offers highly effective pain relief with ...
... Adopts InterviewDirect to ... Positions, CHERRY HILL, N.J., Oct. 22 ... telephone-based job candidate screening solutions,today announced that ... InterviewDirect service to pre-qualify job candidates for ...
... Science,Applications International Corporation (NYSE: SAI ) ... University of Kent on behalf of the United,Kingdom ... projects. Fostered by efforts of the UK ... cooperation from academia, industry and government in,collaborative research ...
... (Oct. 22, 2007)Work done in part by researchers at ... led to the discovery of two genes that cause ... The findings are published in the Oct. 21 online ... on the genetic basis for common and complex diseases. ...
... elderly patients with lung cancer has changed little despite ... The study by Harvard University, National Cancer Institute, and ... December 1, 2007 issue of CANCER, a peer-reviewed journal ... rose by less than one month between 1983 and ...
... other injuries at bay, experts say , , SUNDAY, Oct. 21 ... that Halloween is a treat for both children and adults, ... organization based in Chicago. , "We can keep Halloween safe ... Garrett, the group,s senior vice president, said in a prepared ...
Cached Medicine News:Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 2Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 3Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 4Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 5Health News:Voltaren(R) Gel Receives US Regulatory Approval as the First Approved Topical Prescription Treatment for Pain Associated with Osteoarthritis 6Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 2Health News:Albert Einstein Healthcare Network Turns to InterviewDirect to Qualify Job Candidates 3Health News:SAIC to Collaborate with UK Biometrics Institute 2Health News:SAIC to Collaborate with UK Biometrics Institute 3Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 2Health News:UT rheumatologists discover 2 genes related to disabling form of arthritis 3Health News:Spending more for lung cancer treatment did not substantially increase patients' lives 2Health News:Eye on Safety Makes Halloween Less Scary 2
The license agreement for the manufacturing and distribution of Bulgari eyewear was signed by Luxottica Group in 1997.,Bulgari eyewear is designed for sleek, select people who want to distinguish the...
... agreement between Brook Brothers and Luxottica ... by lightweight materials and a slender ... the unique features of the style ... with classic style and affordable to ...
... Ray-Ban brand debuted in 1937 with the ... was added to Luxottica Group's brand portfolio ... show business celebrities since day one, Ray-Bans ... far the best-selling sunglasses in the world. ...
... Group has been manufacturing the Anne Klein ... Klein eyewear collections are designed for an ... wear Anne Klein eyewear identifies herself with ... refined career woman who is image-conscious and ...
Medicine Products: